pros and cons of glp 1 2026 Employee Benefits Trends: Should You Cover GLP‑1s for Weight Loss? Managing GLP-1/GIP side effects with

Description

Aron will review with you what is medically appropriate for you, and also provides her wealth of knowledge and decades of medical weight loss experience

Catherine Varney, the obesity medicine director for UVA Health, the health system affiliated with the University of Virginia in Charlottesville

Amgen reports maridebart caftaglutide (Maritide) in their pipeline

doi: 10.4239/wjd.v15.i5.818, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 32

Providers increasingly encounter patients Read More Protecting Muscle While Treating Obesity: New Protein Targets for Older Adults on GLP-1s Jun 16, 2026 Articles, Diet and Nutrition, Exercise, Geriatric Medicine, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity 1,502 views The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment